Every day, 10,000 people in the United States reach the age of 65. What do today's seniors want from health care and consultant pharmacy as they age in a variety of living and care settings? Are there insights from the Eden Alternative and the Green House Project that can inform how we move forward as a profession? Do evidence-based triggers for consultant pharmacist involvement work in settings such as geriatric emergency rooms? To open the annual meeting, Dr. Bill Thomas, an international authority on geriatric medicine and eldercare, will share his wisdom about changing perceptions of aging and their impact on the provision of health care. At the conclusion of this knowledge-based activity, the participant will be able to: 1. Describe the age demographic impacting the United States; 2. List the different expectations held by "today's seniors" with regard to healthcare; 3. List the different expectations held by "today's seniors" with regard to consultant pharmacist services; 4. Identify major tenets of the Eden Alternative and Greenhouse Project; 5. List three evidence-based triggers that prompt consultant pharmacist involvement in geriatric emergency rooms. Universal Activity Number: 0203-0000-11-113-L04-P; 1.0 contact hour
Download Handout

The armamentarium of antidiabetic agents continues to grow with the emergence of several new agents to help providers and patients reach and maintain glycemic control. This activity will provide foundational knowledge on the risks associated with poor glycemic control and the strategies to achieve glycemic targets. Upon completion of this knowledge-based activity, the participant will be able to: 1. Recognize the importance of appropriate goal-setting in older adults with T2DM; 2. Evaluate treatment options for older adults with type 2 diabetes and consider their impact on comorbid disease; 3. Implement practical strategies to defeat persistent barriers to effective insulin treatment; 4. Compare the therapeutic profiles of incretin-based therapies and the safe use of these agents, particularly in combination with other antidiabetic agents. Universal Activity Number: 0203-9999-11-110-L01-P; 1.5 contact hours

Alzheimer's disease (AD) is an irreversible, progressive brain disorder that gradually destroys a person's cognitive abilities. Along with deterioration of cognitive function, nearly all individuals affected by AD also experience behavioral and neuropsychiatric disturbances, such as anxiety, depression, agitation, delusions, and hallucinations. The goal of this continuing education activity is to expand the ability of senior care pharmacists to optimize the management of AD in order to delay worsening of symptoms, preserve cognitive function, and help control behavioral symptoms, ultimately improving the quality of life for patients with AD. At the conclusion of this activity, the participant will be able to: 1. Implement strategies to support accurate and early identification of patients with Alzheimer's disease; 2. Describe the need for the stage-specific management of patients with Alzheimer's disease; 3. Outline the optimal use of pharmacologic and non-pharmacologic approaches in the management of Alzheimer's disease; 4. Recommend medication regimens to minimize polypharmacy and medication adverse events in patients who have moderate to severe Alzheimer's disease. Universal Activity Number: 0203-9999-11-116-L01-P; 1.5 contact hours

This program is designed to provide consultant pharmacists with current information on newly developed oral anticoagulants and to increase their knowledge and skills required to promote the appropriate management of patients. At the conclusion of this activity, the participant will be able to: 1. Discuss the recently approved oral anticoagulants dabigatran etexilate and rivaroxaban, and agents being developed, such as apixaban and betrixaban, including their potential indications, roles, advantages, and disadvantages in senior patients and specific patient populations; 2. Describe the advantages and disadvantages of using the novel oral anticoagulants in comparison to traditional agents, such as warfarin and heparins; 3. Discuss key concepts and summarize the recent literature of new anticoagulant agents dabigatran etexilate and rivaroxaban; 4. Design a plan for determining appropriate candidates to receive the new anticoagulants, dabigatran and rivaroxaban; 5. Develop strategies to manage bleeding complications in patients receiving dabigatran and rivaroxaban and assure the safe use of novel oral anticoagulants during the perioperative period. Universal Activity Number: 0203-0000-11-114-L01-P; 1.25 contact hours
Download Handout

This unique, case-based workshop activity will address the optimal approaches for the prevention, identification, and treatment of MRSA infection in older adults, ultimately reducing the burden of MRSA infection in older adults. At the conclusion of this activity, the participant will be able to: 1. Discuss the need to improve infection control policies and procedures to prevent the spread of MRSA infections; 2. Describe ways to improve the identification of MRSA infection in the LTC setting; 3. Outline the application of the updated IDSA guidelines for the management of MRSA infections in older adults; 4. Compare the advantages and disadvantages of various antimicrobial agents for treatment of MRSA infection. Universal Activity Number: 0203-9999-11-143-L01-P; 1.25 contact hours
Download Handout

Attending pharmacy "Professor Gadget's" presentation will provide the learner with a selection of the latest and greatest technology tools and apps. Bill Felkey is widely renowned in the pharmacy world for his insights on what works and what fails in pharmacy technology and mobile apps for the clinical pharmacist. He will demonstrate the most current apps for your mobile devices and help differentiate which app is best for your practice. You will be overwhelmed with the options that are available to you, but only you can decide whether these are tools or toys. At the conclusion of this session, the participant will be able to: 1. Identify pharmacy technology resource websites to evaluate their technology footprint for practice; 2. Implement new technology applications into their consulting practice; 3. Select appropriate "to the bedside" clinical applications to enhance patient care; 4. Differentiate and incorporate mobile apps (applications) into their decision making process; 5. Define how technology will respond to health care reform initiatives under way. Universal Activity Number: 0203-0000-11-115-L04-P; 1.25 contact hours
Download Handout

Download Handout

Download Handout

Attendees will gain a better understanding of requirements for medication regimen review (MRR) in the assisted living environment. They will gain new knowledge of the benefits of MRR in assisted living and how the principles of MRR now practiced in nursing facilities can be applied to assisted living. Audience members will learn about the barriers to increasing pharmacist's MRR responsibilities in assisted living. They will also learn arguments that they can use in their respective states to increase the pharmacist's role in this environment. At the conclusion of this activity, the participant will be able to: 1. Discuss the differences between federal and state regulations governing medication regimen review in nursing facilities and assisted living facilities; 2. Review the agencies responsible for regulating pharmacy services provided to assisted living facilities; 3. Identify states with the most rigorous requirements for MRR in the assisted living environment; 4. List at least four ways in which pharmacists can improve pharmaceutical services in assisted living; 5. Discuss steps that could be taken to create state-specific initiatives to increase the requirements for MRR in assisted living. Universal Activity Number: 0203-0000-11-117-L04-P; 1.25 contact hours
Download Handout

This session will focus on the significant opportunity for consultant pharmacists to work with managed care. LTC consultant pharmacists have in general overlooked the opportunity to partner with managed care organizations. Opportunities include formulary management, clinical opportunities, transitions of care, and improvement of medication management protocols in nursing homes. This session will teach consultants about opportunities to partner with managed care. At the conclusion of this activity, the participant will be able to: 1. Recognize challenges managed care faces in nursing homes; 2. Understand clinical opportunities to partner with managed care; 3. Understand how contracting may impact medication management; 4. Recognize how communication issues impact the formulary exception process; 5. Learn about consultant's role in transitions of care. Universal Activity Number: 0203-0000-11-119-L04-P; 1.25 contact hours
Download Handout

Approximately 2.2 million people in the United States have been diagnosed with AF, the most common cardiac arrhythmia, and the risk of stroke in these patients is substantial. Patients with AF have a five-fold increased risk for stroke. In older adults, AF leads to 25% of all strokes, and stroke is the leading cause of long-term disability and the third leading cause of death in the United States. Because of the rapid and serious consequences of stroke, effective preventive treatment is of utmost importance to reduce disability and improve survival in older adults with AF. Senior care pharmacists are in a critical position to improve stroke prevention in elderly patients with atrial fibrillation. However, our needs assessment reveals that senior care pharmacists face many challenges in ensuring that these patients receive optimal anticoagulation therapy. Senior care pharmacists have the opportunity to reduce the risk of stroke in patients with AF by expanding their ability to facilitate the optimal use of anticoagulation therapy in older adults with AF. Also, as data on new and emerging therapies become available, senior care pharmacists need to remain up-to-date in order to continue providing optimal care based on current evidence. The goal of this continuing education activity for senior care pharmacists is to expand their knowledge and skill in best practices related to stroke prevention in older adults with AF, ultimately reducing stroke-related disability, dementia, and death in older adults with AF. At the conclusion of this activity, the participant will be able to: 1. Identify the major barriers that are causing patients with AF to receive suboptimal anticoagulation; 2. Determine when the risk for stroke in older adults with atrial fibrillation exceeds the risk for anticoagulation-associated bleeding; 3. Assess the comparative benefits and risks of anticoagulant therapy to prevent stroke in patients with atrial fibrillation; 4. Explain differences in the pharmacokinetic and pharmacodynamic profiles of new and emerging oral anticoagulants. Universal Activity Number: 0203-9999-11-147-L01-P; 1.25 contact hours
Download Handout

This session will consist of debates on two controversies within the practice of geriatrics. Recommending the use of calcium supplements in osteoporosis has always seemed so cut-and-dry, however literature support of adverse cardiovascular outcomes with calcium supplementation seems to continue to be published in high impact medical journals. The first debate will help the senior care pharmacist who may be confused about what now to do with their osteoporotic patients. The second debate will focus on if and when memantine or cholinesterase inhibitors should be stopped. So many times, the senior care pharmacist is faced with an advanced stage dementia patient for whom there is a question of the continued utility of dementia pharmacotherapy. This program will appeal to the senior care pharmacist who has wondered what evidence exists to support such controversies and hopes to answer many questions. At the conclusion of this activity, the participant will be able to: 1. Describe the evidence supporting whether or not to use calcium supplementation in a patient with a history of cardiovascular disease; 2. Formulate a calcium recommendation for the patient with osteoporosis, given the evidence; 3. Explain the evidence supporting continuing the use of a cholinesterase inhibitor or memantine in the advanced stage dementia patient; 4. Defend a recommendation to stop a cholinesterase inhibitor or memantine in an advanced stage dementia patient; 5. Distinguish between high-level evidence and low-level evidence when making an argument for or against a recommendation. Universal Activity Number: 0203-0000-11-118-L01-P; 1.25 contact hours
Download Handout

This session describes the health service delivery and current pharmacy practice environment in Hong Kong. It details how pharmacists in Hong Kong established an MTM training and certification program and gives an overview of the steps taken to launch territory-wide community-based MTM services. The MTM movement is in alignment with the local government's health care reform objectives. By collaborating with partners from abroad with expertise in different areas of pharmacy practice, the Hong Kong pharmacists are seeking to set a best practice model for other Asian countries. At the conclusion of this activity, the participant will be able to: 1. Describe the conditions in Hong Kong that prompted the initiation of the Global Drug Safety movement; 2. Gain an overview of the actions taken to promote drug safety in Hong Kong; 3. Review the attitude of a pilot group of patients in Hong Kong towards their medication therapy; 4. Describe how to establish collaborations with global partners in establishing training and professional advancement; 5. Review how Hong Kong established a novel MTM program that fits into health care reform objectives, with quality matrix to track outcomes. Universal Activity Number: 0203-0000-11-120-L04-P; 1.0 contact hour
Download Handout

This course will teach attendees how to use the right legal entities in the right way to ensure protection of both their business and personal assets from any lawsuit. This level of protection may, in many cases, also decrease malpractice insurance costs. C-Corps, S-Corps, and LLC's are only part of the answer. In addition, these same tools can drastically reduce income taxes while eliminating both capital gains and estate taxes. Upon completion of this course attendees will have a clear understanding of how the legal system can be used in their favor and never leave them victim again. At the conclusion of this knowledge-based activity, the participant will be able to: 1. Identify why incorporating may not help prevent lawsuits; 2. Identify how to use the only legal tool that can protect 100% of a business owner's professional and personal assets from lawsuits, liens, and levies; 3. List what a living trust will and will not do; 4. Describe how to protect a business, property, retirement funds, and assets in the event of a judgment in excess of liability insurance or exclusions in a policy; 5. Identify which state laws provide the greatest asset protection. Universal Activity Number: 0203-0000-11-121-L03-P; 1.0 contact hour
Download Handout

A brief overview of geriatric pharmacokinetic and pharmacodynamics principles will be discussed to develop baseline knowledge of pharmacotherapy concerns. A variety of commonly seen cases of medication underuse and polypharmacy will be discussed as reported in current literature and practice. Evaluation of a patient case series will serve as the active learning method of this session. After attending this session, attendees will possess a clearer understanding of the complexity of the drug regimen of the geriatric patient. At the conclusion of this knowledge-based activity, the participant will be able to: 1. Describe the pharmacokinetic and pharmacodynamic changes that affect geriatric pharmacotherapy; 2. Identify commonly occurring scenarios of medication underuse or polypharmacy most likely to contribute to adverse outcomes in the elderly; 3. Evaluate techniques available to assess drug therapy appropriateness in the elderly; 4. Assess a patient scenario depicting underuse or polypharmacy using principles of drug regimen review; 5. Recommend appropriate interventions to optimize medication therapy. Universal Activity Number: 0203-0000-11-122-L01-P; 1.0 contact hour
Download Handout

Continuing pharmacy education credit is not provided for this session.

Overactive bladder (OAB) is the most common cause of urinary incontinence or loss of bladder control in adults and affects approximately 33 million Americans. While OAB affects people of all ages, the medical issue of OAB is of particular importance in the older adult population, with prevalence greatly increasing in older adults. The symptoms of OAB -- urge urinary incontinence (UI), urgency, and urinary frequency -- often lead to further medical and psychological problems and can have a devastating impact on quality of life. Senior care pharmacists have the opportunity to improve outcomes for older adults with OAB by more thoroughly identifying patients who suffer from OAB, by more consistently providing effective OAB treatment, and by increasing the use of strategies to promote patient adherence to OAB treatment recommendations. The comprehensive goal of this activity is to expand the ability of senior care pharmacists and other senior care clinicians to provide optimal management for older adults experiencing OAB, ultimately improving outcomes for the many older adults who suffer from OAB. At the conclusion of this activity, the participant will be able to: 1. Develop effective treatment plans for older adults with overactive bladder; 2. Evaluate the efficacy and safety of new and emerging therapies for adults with overactive bladder; 3. Communicate with patients realistic goals of overactive bladder treatment; 4. Minimize medication side effects in treatment plans for older adults with overactive bladder. Universal Activity Number: 0203-9999-11-142-L01-P; 1.25 contact hours
Download Handout

This general session will be a platform for ASCP members to learn more about recent proposed regulation from the Centers for Medicare and Medicaid Services (CMS) to mandate separation between consultant pharmacists and long-term care dispensing pharmacies and pharmaceutical manufacturers. Participants will learn more about the proposed rule and ASCP's position on separation of consulting and dispensing services. Participants will also have an open forum to discuss the potential impact of the regulation on the profession and ASCP. At the conclusion of this knowledge-based activity, the participant will be able to: 1. Summarize the policy justification given for the CMS rule; 2. Identify major components of the regulation in relation to consultant pharmacy; 3. Evaluate the impact of the rule on their practice; 4. Describe ASCP's established position on separation of clinical and dispensing pharmacy services; 5. List available ASCP resources for response to and compliance with the proposed rule. Universal Activity Number: 0203-0000-11-124-L03-P; 1.25 contact hours
Download Handout

This session will include a brief discussion of the pathophysiology of hypertension in the elderly and how critical organ systems are affected. A review of recent clinical studies and highlights/major recommendations from national guidelines will be included. Attendees will benefit from attendance by gaining a better understanding of how antihypertensives are properly initiated, titrated, and monitored in elderly patients. The attendee also will be better prepared to provide treatment and monitoring recommendations to prescribers by reviewing and analyzing the latest clinical trial guideline information pertaining to hypertension in the elderly. At the conclusion of this knowledge-based activity, the participant will be able to: 1. Recognize the cardiovascular risks of untreated hypertension in the elderly; 2. Review the most recent clinical trial information available to evaluate antihypertensive treatment regimens and blood pressure goals in geriatric patients; 3. Outline major treatment recommendations from published guidelines for the management of hypertension in the elderly; 4. Discuss proper initiation, titration, and monitoring of antihypertensive pharmacotherapy in elderly patients; 5. Utilize patient cases to define the consultant pharmacist's role in the management of geriatric patients with hypertension: identification, recommendations, counseling, and adherence. Universal Activity Number: 0203-0000-11-137-L01-P; 1.25 contact hours
Download Handout

You're probably thinking, "Why should I take on a residency?" or "How do I even get started?" A residency can open up doors to new opportunities and provide exposure to areas of pharmacy practice you never knew existed. The residency process can be daunting, but the proper tools and some helpful hints can make navigating the process significantly easier. During this session you will speak with the "insiders," residents and directors who have been through the process. They will provide insight on their experiences through the residency process. After this session, you should walk away feeling inspired, motivated, and ready to "Make the Match." Learning Objectives: 1. Explain the importance of considering a residency: Why should I be interested? 2. Review the residency timeline: What do I do and when do I do it? 3. Present helpful tips and practical advice: Hear from the insiders (Director and Residents) 4. Describe methods to help you stand out during the process: Add "Bling Bling" to your portfolio. 5. Provide answers to commonly asked questions: Q&A session. Continuing pharmacy education credit is not provided for this session.

This session will discuss the role of biologics for inflammatory conditions in senior care. As utilization trends continue to increase, senior care pharmacists often must evaluate these therapies as part of overall care plans for seniors with inflammatory conditions such as rheumatoid arthritis, psoriasis, psoriatic arthritis, and Crohn's disease. This session with provide insight on these approved therapies noting their place in therapy, intricate nuances, and clinical attributes. Key considerations for the senior care pharmacists when conducting medication regimen review for seniors on biologics will also be explored. At the conclusion of this activity, the participant will be able to: 1. Discuss the increasing utilization of biologics for inflammatory conditions within senior care settings; 2. List the various biologic agents currently FDA-approved for treating inflammatory conditions, highlighting those approved for rheumatoid arthritis; 3. Describe key clinical attributes of each biologic agent, including special considerations when utilized in the geriatric population; 4. Outline integral components of a pharmaceutical care plan for geriatric patients on biologic agents; 5. Identify clinical monitoring parameters for biologics that should be evaluated during consultant pharmacist medication regimen review. Universal Activity Number: 0203-0000-11-127-L01-P; 1.0 contact hour
Download Handout

This workshop offers practical training for pharmacists to improve their skills in conducting and incorporating cognition, literacy, and pillbox assessments in their MTM practice. Methods for administering efficient cognitive, literacy, and pillbox skill screens and respective scoring systems will be presented. Individuals may request one-on-one feedback for skill refinement that will aid them in their respective practice setting. At the conclusion of this activity, the participant will be able to: 1. Demonstrate the value of using cognitive and pillbox skills assessments during MTM and for patients and caregivers experiencing care setting transitions; 2. Administer and score Mini-Cog according to standardized methods; 3. Administer and score Montreal Cognitive Assessment (MoCA); 4. Administer and score a pillbox organizational skills assessment; 5. Interpret screening results, distinguish the educability of the patient, and provide individualized education to improve medication management skills. Universal Activity Number: 0203-0000-11-125-L04-P; 1.0 contact hour
Download Handout

A significant majority of older adults experience pain that may interfere with normal functioning. The ramifications of this extend far beyond the pain itself, increasing the risk of depression, care complexity, sleep problems, and hospitalization, as well as reducing patient quality of life and increasing overall costs. Numerous barriers interfere with the ability of clinicians to provide adequate pain management for residents, including regulatory and reimbursement issues, patient comorbidities, concern about side effects, and the cognitive issues and dementia many of these patients experience. At the conclusion of this knowledge-based activity, the participant will be able to: 1. Review the pathophysiology of different types of pain that are common in the older patient population; 2. Describe how pain management strategies should be tailored based on the type of pain; 3. Develop policies and programs that can be implemented in the long-term care setting to improve the management of pain; 4. Outline ways to improve pain management in older adults who have cognitive impairment and/or dementia. Universal Activity Number: 0203-9999-11-154-L01-P; 1.0 contact hour

Sex is a universal activity and health issue that does not diminish or change just because one ages. This interactive session will discuss at least eight important issues that pharmacists need to be familiar with. This session will utilize a dialogue format with audience participation utilizing case studies that will address these important issues. At the conclusion of this activity, the participant will be able to: 1. Describe the taboos and changes in sexual behavior in older adults; 2. Identify the need for intimacy as one ages as well as how intimacy and loss influences sexual attitudes in younger vs. older adults; 3. Discuss homosexual relationships among the older population; 4. Discuss the changing epidemiologic patterns of sexually transmitted diseases (STDs) across the life spectrum as well as medication considerations for the treatment of STDs in the older population; 5. Discuss common chronic illnesses associated with sexual health concerns along with medications that will influence sexual health. Universal Activity Number: 0203-0000-11-126-L01-P; 1.0 contact hour
Download Handout

The need for pharmacists to provide services for the ambulatory, community dwelling geriatric population is growing. For participants seeking to expand services to this population, this session will present a reproducible model for developing skills and delivering comprehensive services including MTM. The session will highlight essential components of this model and present findings of targeted efforts during the past five years that increased access to the Medicare Part D prescription drug benefit, optimized drug therapy outcomes, lowered out-of-pocket costs, and reduced health disparities in vulnerable Medicare beneficiaries. In addition, this session will summarize variables that determine the consumer's perceived value and thus willingness to pay for MTM services. Pharmacist challenges to providing MTM, such as unclear reimbursement terms, lack of time, or staffing, will be presented. Strategies to increase the effectiveness of MTM provision and clinically stimulating aspects of MTM, including increased physician acceptance of recommendations, will be shared. At the conclusion of this activity, the participant will be able to: 1. Define necessary elements of instruction prior to conducting a program including the ability to identify the least costly Medicare Part D stand-alone prescription drug plan based on beneficiary-specific information; 2. Indicate effective methods to identify and communicate medication-related issues to medical providers; 3. Identify and provide necessary vaccinations for Medicare beneficiaries; 4. Define beneficiaries' willingness to pay as a function of demographics, economic status, and other factors; 5. Provide ideas for sustainability of MTM into the future. Universal Activity Number: 0203-0000-11-129-L04-P; 1.5 contact hours
Download Handout

At the conclusion of this activity, the participant will be able to: 1. Appropriately assess behavioral problems in a patient with dementia; 2. Use a stepwise approach to select treatment strategies for behavioral problems in patients with dementia; 3. Determine when an antipsychotic might be appropriate to treat behavioral problems in a patient with dementia; 4. Select the most appropriate antipsychotic for a specific patient based on comorbidities and risk for potential adverse effects; 5. Monitor antipsychotic therapy for efficacy/safety and adjust dose/discontinue therapy as indicated. Universal Activity Number: 0203-0000-11-130-L01-P; 1.5 contact hours
Download Handout

The older segment of the United States population is quickly growing and future pharmacists must be well-prepared to care for this group of complex patients. Creating valuable clerkships offering exposure to the practice of geriatric pharmacy is vital during the experiential pharmacy curriculum, both in introductory and advanced pharmacy practice experiences. Within traditional long-term care dispensing and other consulting pharmacy settings, it is often challenging for a pharmacist to carry out day-to-day responsibilities while fulfilling an appropriate teaching role. However, pharmacy students on clerkships can also assist consultant pharmacists with many aspects of their practice, increasing efficiency and job satisfaction. The wide-ranging information offered in this interactive session will be of interest to pharmacists who already work with students as well as those who would like to explore the benefits of incorporating students into their practice. Case scenarios will be discussed in small groups to facilitate networking among participants. All five stations will provide sample materials. The session will highlight potential benefits of precepting for the consultant pharmacist. Experiential student training, teaching opportunities, and ASCP student chapter involvement will be discussed. The process of creating learning objectives and establishing a structured schedule for students in your practice will be demonstrated. Participants will walk through the process of conducting a journal club discussion as a means of experiential teaching. Successful strategies for providing constructive feedback to students in varied clinical settings will be shared. Common ethical dilemmas that occur during the course of medication therapy management of older adults will be discussed along with strategies for resolution that can be modeled for students. At the conclusion of this application-based activity, the participant will be able to: 1. Highlight the benefits of partnering with a College/School of Pharmacy as a consultant pharmacist; 2. Discuss considerations for developing a rotation, including preceptor and student responsibilities, academic requirements, interdisciplinary activities, and the resources that are available to assist in creating a positive rotation experience; 3. Demonstrate the skills necessary for conducting a critical analysis and discussion of primary literature publications with pharmacy students; 4. Evaluate strategies for providing feedback to students in varied clinical settings; 5. Discuss ethical issues that may arise during a student rotation experience and how to address them appropriately. Universal Activity Number: 0203-0000-11-131-L04-P; 1.5 contact hours
Download Handout

Download Handout

This session presents reviews of current literature on geriatric pharmacotherapy topics. The session will be structured as 15-minute presentations by four speakers who have experience in geriatric pharmacotherapy practice and research. Each session will provide a review of a peer-reviewed article published within 12 months prior to the presentation date. The presentation will provide a review of the study design and methods, population demographics, data analysis, results, and discussion. Each speaker will summarize the relevance of the findings for consultant pharmacy practice. At the conclusion of this knowledge-based activity, participants will be able to: 1. Review basic principles of literature review and analysis; 2. Discuss current topics in geriatric pharmacotherapy; 3. Present summaries of recent literature on geriatric pharmacotherapy topics. Universal Activity Number: 0203-0000-11-128-L01-P; 1.5 contact hours
Download Handout

"In 1921, before most of us were born, a remarkable study began tracking the loves and lives of 1500 Americans from childhood to death. The study continues even today, with research teams led by Howard Friedman still keeping tabs on the remaining few who are still alive and analyzing massive amounts of data to establish what it is precisely about these 1500 individuals that led some to stay well and others to fall ill or die before their time. Incredibly, no one until now has chronicled and interpreted the findings from this monumental almost century-long project for the general public. Is longevity associated with being married, daily jogs, living with pets, or faith in God? At last, with lucid prose and rigorous yet crystal clear analysis, Professor Friedman ...(has) succeeded beautifully." -- Sonja Lyubomirsky, author of The How of Happiness: A Scientific Approach to Getting the Life You Want. At the conclusion of this knowledge-based activity, the participant will be able to: 1. Describe individual differences in healthy aging; 2. Identify new understandings of healthy "stress"; 3. Explain the multifaceted nature of conscientiousness; 4. List Key Life-span Pathway models, including situation selection; 5. Avoid Research and Treatment artifacts (biases) due to personality selection and differential mortality; 6. Describe the importance of social ties and meaningful work or activity to healthy aging. Universal Activity Number: 0203-0000-11-132-L04-P; 1.0 contact hour
Download Handout

Attendees will receive answers to the most current and pressing questions regarding LTC today. These discussions include changing delivery models, such as ACOs, as well as changes in who is responsible for payment of medications used by NH residents. Special medication management issues involving ESRD medications and those utilized off-label will be discussed. In addition, attendees will have an opportunity to ask their most important questions. This discussion will provide a foundation for consultant pharmacists to lead in NHs through a changed and changing environment. At the conclusion of this activity, the participant will be able to: 1. Describe how health care reform will impact LTC; 2. Describe the role of NHs in Accountable Care Organizations (ACO) and how can a NH deliver on the outcomes it will be held accountable? 3. Describe the medications that are not included in the NH Part A PPS payment and instead can be billed separately; 4. List the medications that are now bundled into the ESRD payment; 5. Describe how NHs are being viewed as being accountable for the use of medications off-label. Universal Activity Number: 0203-0000-11-134-L04-P; 1.5 contact hours
Download Handout

This session is an introduction to aging and care of older adults. Topics include the demographics of aging in the United States, physiological changes associated with aging, goals of drug therapy in older adults, and the philosophy of person-centered care. Clinical practice guidelines (CPGs) will be discussed, reviewing benefits and risks of CPGs in the older adult population. At the conclusion of this knowledge-based activity, the participant will be able to: 1. Identify the demographic trends related to the aging American population; 2. List the physiologic changes that occur in aging adults; 3. Describe the care process and how breakdowns in the care process lead to medication-related problems in older adults; 4. Delineate the benefits and risks of applying clinical practice guidelines to older patients. Universal Activity Number: 0203-0000-11-133-L01-P; 1.5 contact hours
Download Handout

Download Handout

Update your knowledge of new pharmaceuticals that have recently been released or will be released in the near future. This candid and informative presentation also will highlight key features of the new drugs and discuss their role within currently available therapies. At the conclusion of this knowledge-based activity, the participant will be able to: 1. Assess new trends in drug development; 2. Explain indications, pharmacology, adverse effects, and dosing of the products discussed; 3. Determine the role these products will play in the participant's practice; 4. Evaluate the economic implications of these choices; 5. Examine products in the short-term pipeline that will be important to the practice of the participants. Universal Activity Number: 0203-0000-11-135-L01-P; 1.5 contact hours
Download Handout

Long-term and post-acute care pharmacy is an ever-evolving landscape. ASCP members, with their unique knowledge of the long-term care and geriatric population, will continue to stand at the forefront of this frontier, combining their business acumen with their expertise in pharmacotherapy to provide patient-centered medication management. This activity will discuss the Center for Medicare and Medicaid Innovation, the Partnership for Patients campaign, and opportunities for ASCP members to engage in innovative community-wide care transition initiatives. Presenters will also discuss the new 2011 Annual Report for Long-Term Care Pharmacies and Consultant Pharmacists resulting from the Benchmarking Survey conducted this fall. As physicians, hospitals and long-term care facilities adopt the electronic health record, the pharmacist's role in using technology for medication management outside the prescription process will expand. The Pharmacy e-Health Information Technology Collaborative is an organization focused on influencing the structure, development, and implementation of the U.S. health information technology (HIT) infrastructure so that the profession's needs are addressed and integrated into the national HIT framework. During this session, you will learn how the efforts of the Pharmacy e-HIT Collaborative will impact the future of pharmacy and patient care throughout the spectrum of care, including consultant pharmacists in the long-term and post-acute care settings. At the conclusion of this activity, the participant will be able to: 1. Describe the Center for Medicare and Medicaid Innovation initiatives and the Partnership for Patients campaign; 2. Identify ways that pharmacists can engage in innovative community-wide care transition initiatives; 3. Summarize the process and categories of results of the 2011 Annual Report for Long-Term Care Pharmacies and Consultant Pharmacists resulting from the Benchmarking Survey conducted this fall; 4. Describe how the efforts of the Pharmacy e-HIT Collaborative will impact the future of pharmacy and patient care. Universal Activity Number: 0203-0000-11-155-L04-P; 1.0 contact hour
Download Handout

The objective of this session is to provide the consultant pharmacist a working knowledge and understanding of "deprescribing." For years, deprescribing has been known as "therapeutic debridement" and more recently referred to as performing a "drugectomy." The attendee will learn what deprescribing is and, more importantly, be presented the published peer-reviewed evidence supporting safe deprescribing. Clinical cases will be presented and practical approaches on how to implement deprescribing recommendations to improve the safety of older adults will be explored. At the conclusion of this activity, the participant will be able to: 1. Define and describe "deprescribing"; 2. State clinical situations where a dosage decrease or discontinuation of therapy may increase patient safety; 3. Develop an appropriate, evidence-based plan to recommend discontinuation of pharmacotherapy; 4. Prepare a "deprescribing" clinical communication. Universal Activity Number: 0203-0000-11-123-L04-P; 1.0 contact hour
Download Handout

This session will focus on the risk of adverse drug events in older adults. Geriatric syndromes, potentially inappropriate medications, and the prescribing cascade also will be addressed. At the conclusion of this knowledge-based activity, the participant will be able to: 1. Identify the unique risks and occurrence of adverse drug effects in older adults; 2. List the most common geriatric syndromes and explain them; 3. Identify the most common potentially inappropriate medications for older patients; 4. Define the prescribing cascade and explain how to combat its insidious effects. Universal Activity Number: 0203-0000-11-136-L01-P; 1.0 contact hour
Download Handout

Download Handout

Participants will understand proposed, new, and existing privacy and security standards for patient health information. Participants will receive information regarding timelines and compliance strategies. This session will provide an overview of hacking techniques for electronic information and advice to manage electronic infrastructure. At the conclusion of this activity, the participant will be able to: 1. Understand existing, proposed, and updated federal regulations governing privacy of health care information; 2. Receive compliance strategies and information on timelines; 3. Receive an overview of current hacking techniques used to compromise electronic health information; 4. Gain an understanding of evaluating electronic infrastructure to ensure the protection of patient information, ensure operational continuity, and more easily adapt to regulations and technologies as they occur. Universal Activity Number: 0203-0000-11-138-L03-P; 1.0 contact hour
Download Handout

This session will build upon basic principles discussed in the previous Core Basics sessions, Geriatrics 101 and Geriatrics 102. Case studies will be used to illustrate review of the drug regimen in the older adult. Emphasis will be on identifying and resolving medication-related problems in older adults. At the conclusion of this application-based activity, the participant will be able to: 1. Apply the four steps of the care process to the unique situation of the elderly patient; 2. Identify and intervene on the eight types of medication-related problems that occur in older patients; 3. Engage in focused, organized, and beneficial drug regimen reviews of geriatric case examples. Universal Activity Number: 0203-0000-11-139-L01-P; 1 contact hour
Download Handout

In 2007, the Food and Drug Administration (FDA) received a congressional mandate to implement Risk Evaluation and Mitigation Strategies (REMS). This activity will focus on the various types of REMS, common medications with REMS, and implications for these requirements in various senior care settings and to pharmacy providers. At the conclusion of this activity, the participant will be able to: 1. Explain the FDA Amendments Act of 2007 and the inclusion of risk evaluation and mitigation strategies (REMS); 2. List the components of a REMS program; 3. Discuss how REMS apply in the senior care setting; 4. Describe commonly used medications with REMS in the senior care setting; 5. Develop a strategy for implementing and managing REMS in the senior care setting. Universal Activity Number: 0203-0000-11-140-L04-P; 1.0 contact hour
Download Handout

There truly is an art and science to the conversations and decisions surrounding the discontinuation of medications in hospice patients. This presentation will explore eight decision models, with case examples, highlighting key factors. Comparison and contrast will also be made with known screening tools of inappropriate medication prescribing, such as the Beers List, STOPP, and the Good Palliative-Geriatric Practice Algorithm. You will reinforce your current knowledge, learn new tools, and incorporate concepts such as goals of care, risk versus benefit, and time until benefit into your practice. At the conclusion of this activity, the participant will be able to: 1. Discuss two factors involved in the decision on when to consider the discontinuation of warfarin in a hospice pharmaceutical plan of care; 2. Name two medications that may be considered futile and therefore inappropriate in a hospice pharmaceutical plan of care; 3. List three decision models for medication discontinuation in hospice patients; 4. Explain the concept of time until benefit as related to aspirin or statin use in a hospice pharmaceutical plan of care; 5. Compare and contrast the Beers List with STOPP. Universal Activity Number: 0203-0000-11-141-L04-P; 1.0 contact hour
Download Handout